2023-09-10 19:34:14
RSV (respiratory syncytial virus), the cause of bronchiolitis, already has three vaccines approved in recent weeks in Europe and the United States. asiraj – stock.adobe.com
The market for treatment against RSV (respiratory syncytial virus), the cause of bronchiolitis, could eventually reach 10 to 12 billion dollars per year.
Three years after the Covid, this is the new playground for Big Pharma. RSV (respiratory syncytial virus), the cause of bronchiolitis, already has three vaccines approved in recent weeks in Europe and the United States. Deliveries have started in some countries.
Last year, the triple influenza-bronchiolitis-Covid epidemic had brought health systems to their knees, barely recovered from two years of health crisis. Bronchiolitis, which particularly affects babies and the elderly, had been particularly severe. “It is rare to see a new market open up in the pharmaceutical industry in this way, notes Vincent Meunier, sector specialist at Bryan, Garnier & Co. Against the RSV, we have gone from a situation of nothingness to a battle between giants.»
Read alsoFinally protection against bronchiolitis in infants
Only one treatment against severe forms existed until then, AstraZeneca’s Synagis. Six decades of research had ended in failure. Worldwide, RSV is the cause each year…
This article is reserved for subscribers. You have 78% left to discover.
Want to read more?
Unlock all items immediately.
Already subscribed? Log in
#battle #pharmaceutical #giants